Inducible Ift88-deficient mice show features consistent with mild pulmonary hypertension
Selina M Garcia1, Benjamin J Lantz1, Helen J Wagner1
1Cell Biology and Physiology Department, The University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.
Global loss of Intraflagellar transport protein 88 (IFT88) in mice caused pulmonary hypertension (PH). This study investigated IFT88
科学分野:
- Cell Biology; Genetics; Physiology
背景:
- Intraflagellar transport protein 88 (IFT88) is crucial for cilia formation and function.; IFT88 mutations are linked to various diseases, including kidney cysts and immune dysfunction.; Endothelial-to-mesenchymal transition (EndMT) plays a role in pulmonary hypertension (PH).
研究 の 目的:
- To investigate the role of global Ift88 loss in the development of pulmonary hypertension (PH).
主な方法:
- Utilized tamoxifen-inducible Ift88 knockout (KO) mice to assess PH.; Evaluated PH indices, including right ventricular systolic pressure and arterial wall changes.; Examined lung tissue for inflammation and EndMT at different time points post-deletion.
主要な成果:
- Global Ift88 KO mice exhibited signs of PH, such as increased right ventricular systolic pressure.; Observed increased cell proliferation in resistance artery walls and arterial wall thickening.; No significant lung inflammation or EndMT was detected at the early time point.
結論:
- Global Ift88 deletion in mice leads to pulmonary hypertension.; The study highlights a potential link between IFT88 and cardiovascular health.; Further research is needed to elucidate the specific mechanisms and cell types involved.
さらに関連する動画
04:54Invasive Hemodynamic Assessment for the Right Ventricular System and Hypoxia-Induced Pulmonary Arterial Hypertension in Mice
Published on: October 24, 2019
08:34Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
関連する概念動画
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
